Senellart H, Bennouna J
Centre René Gauducheau, St Herblain, France.
Rev Mal Respir. 2008 Jun;25(6):767-72. doi: 10.1016/s0761-8425(08)73804-x.
Bevacizumab is a monoclonal antibody against vascular endothelial growth factor that is currently validated for treatment and has shown survival benefit in various cancers, particularly non-small cell lung cancer. However, a very specific toxicity profile has been observed with bevacizumab. This article presents data from the literature concerning hypertension and proteinuria, and provides recommendations for the management of these toxicities.
贝伐单抗是一种抗血管内皮生长因子的单克隆抗体，目前已被证实可用于治疗，并且在多种癌症，尤其是非小细胞肺癌中显示出生存获益。然而，使用贝伐单抗时已观察到一种非常特殊的毒性特征。本文介绍了来自文献中有关高血压和蛋白尿的数据，并提供了针对这些毒性的管理建议。
